Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
A legfontosabb adatok
- Ki végzi
- National Institute of Allergy and Infectious Diseases (NIAID)
- Hol
- Atlanta, Baltimore, Birmingham, Chicago, Great Neck, Houston, Pittsburgh és Rochester (Egyesült Államok)Mind a 8 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 30 fő, tervezett
- Kezdés
- 2026. ápr. 21.
- Várható befejezés
- 2029. aug.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Ublituximab
- Placebo for Ublituximab
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with early, active immune-mediated necrotizing myopathy (IMNM), a muscle disease caused by the immune system, who have anti-SRP or anti-HMGCR antibodies. Ublituximab or placebo is added to their current treatment.
- Életkor
- 18 years or older at disease onset.
- Nem
- All sexes can join.
- A betegség stádiuma
- Definite or probable IIM per the 2017 EULAR/ACR criteria and IMNM per the 2016 ENMC criteria. Muscle weakness or CK rise started within 1 year. MMT-8 score < 142 of 150, CK > 1.5x ULN, and at least 1 other abnormal disease measure.
- Korábbi kezelés
- Must take only one of methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine, tacrolimus or cyclosporine for at least 12 weeks, same dose for at least 4 weeks. Prednisone ≤ 20 mg/day at a stable dose for 4 weeks, or stopped at least 4 weeks before. Cannot have had B-cell depleting drugs such as rituximab ever.
- Biomarker vagy leletérték
- Anti-SRP or anti-HMGCR antibody positive.
A részvétel fő kizáró okai
- End-stage or irreversible muscle damage, severe lung disease or severe swallowing problems, or using a wheelchair.
- Other muscle diseases, including antibody-negative IMNM or cancer-associated myositis.
- HIV, hepatitis B, active hepatitis C, tuberculosis or recent serious infection.
- Cancer in the past 5 years, except non-melanoma skin cancer.
- Pregnant, breastfeeding or planning pregnancy.
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Participant must be able to understand and provide informed consent
- Age 18 years or older at disease onset
- Definite or probable IIM per the 2017 EULAR/ACR classification criteria
- Diagnosis of IMNM, meeting the 2016 ENMC classification criteria and having either of the following antibodies:; Anti-SRP; Anti-HMGCR
- Early disease as defined as onset of objective muscle weakness assessed by a physician and/or CK elevation attributed to IMNM within 1 year of the time of informed consent
- Muscle weakness as assessed by an MMT-8 score < 142 of 150 and CK > 1.5x ULN along with abnormality in at least 1 of the following 4 CSMs at screening:; PhGA ≥ 2 cm; PtGA ≥ 2 cm; Extramuscular global assessment ≥ 2 cm; HAQ-DI ≥ 0.25
- Treatment with only one of the following background immunosuppressant medications for IMNM for at least 12 weeks prior to randomization and the same dose for at least 4 weeks prior to randomization:; Methotrexate up to 25 mg weekly; Mycophenolate mofetil up to 3000 mg daily; Mycophenolic acid up to 2160 mg daily; Azathioprine up to 2.5 mg/kg daily; Tacrolimus up to 0.2 mg/kg daily; Cyclosporine up to 5 mg/kg daily
- Current therapy consisting of glucocorticoid ≤ 20 mg/day of prednisone. The dose must be stable for at least 4 weeks prior to randomization. Participants who stopped treatment with glucocorticoids are eligible if the last dose of the glucocorticoids was at least 4 weeks before the time of informed consent
- Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of birth control, as shown in Appendix 1: Acceptable Contraception Methods for Females of Reproductive Potential, for the entire duration of the study and 6 months after last study drug infusion. Female participants of reproductive potential must have a negative pregnancy test at screening and at baseline
Ki nem vehet részt
- Uncontrolled interstitial lung disease or any other uncontrolled IIM manifestation that in the opinion of the investigator would be likely to require treatment with prohibited medication during the study
- Infection with Mycobacterium tuberculosis (TB) as defined by any of the following:; Positive interferon gamma release assay (IGRA) performed at screening or within 12 weeks prior to the time of informed consent; Indeterminate IGRAs must be repeated (with same or other IGRA per local policy) and shown to be negative. Alternatively, if the assay remains indeterminant, a participant must have a negative purified protein derivative (PPD) skin test. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before randomization
- Received a live or live-attenuated vaccine < 4 weeks before the time of informed consent. Received any other type of vaccine < 2 weeks before the time of informed consent
- Treatment with any immunosuppressive or immunomodulatory agent, such as cyclophosphamide, biologics, and Janus kinase (JAK) inhibitors, except those listed in the inclusion criteria 7 within 12 weeks prior to randomization
- Prior receipt of B-cell depleting agents such as rituximab, ocrelizumab, ofatumumab, or belimumab at any time
- Treatment of IMNM with IVIG or subcutaneous immunoglobulin (SCIG) within 12 weeks of randomization, or prior receipt of more than one cycle of IVIG at any time
- Participant has current or history (within 12 months of screening) of alcohol, drug, or medication abuse
- Use of any investigational drug within 24 weeks of the time of informed consent
- End-stage myositis with end-organ involvement that poses additional risk to the participant or confounds the assessment of the participant in the study. Conditions include but are not limited to advanced symptomatic interstitial lung disease (e.g., Forced Vital Capacity (FVC) <60% and/or requiring oxygen therapy) or severe dysphagia
- Irreversible muscle involvement and/or severe atrophy that will pose additional risk to the participant or confound the assessment of the participant in the study. This includes Muscle Damage VAS ≥ 3 cm at screening, documented history of severe atrophy of multiple muscle groups (based on MRI), and/or wheelchair bound
- Diagnosis of other inflammatory or noninflammatory myopathies, including antibody-negative IMNM, inclusion body myositis, overlap myositis, metabolic myopathies, muscular dystrophies or family history of muscular dystrophy, drug induced, cancer-associated myositis, or endocrine-based myositis (except statin induced anti-HMGCR associated IMNM)
- Severe liver disease, such as signs of ascites or hepatic encephalopathy
- Recent or ongoing bacterial, viral, or fungal infection requiring systemic treatment within 14 days of the time of informed consent
- Current suppressive therapy for any chronic infections including herpes simplex virus (HSV)
- Medical history or serologic evidence at screening of chronic infections, including:; Human immunodeficiency virus (HIV) infection b. Hepatitis B virus (HBV) as indicated by surface antigen or hepatitis B core antibody positivity c. Hepatitis C virus (HCV) as indicated by anti-hepatitis C antibody positivity. If a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if they have a negative viral load at Screening
- Known hypersensitivity reaction to ublituximab
- Any of the following laboratory tests at screening:; Hemoglobin < 10 g/dL b. Absolute white blood cell count < 3,000 cells/mm3 c. Platelet count < 100,000 cells/mm3 d. Absolute neutrophils < 1,500 cell/mm3 e. Peripheral B-cell < 40 cells/µL f. IgG < 690 mg/dL g. Estimated GFR < 50 mL/min/1.73 m2
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study
- History of malignancy (excluding non-melanoma skin cancer) unless cured by adequate treatment, with no evidence of recurrence for ≥ 5 years from the time of informed consent
- Participant is pregnant or lactating or intends to become pregnant during the study
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- Emory University School of Medicine: Division of RheumatologyAtlanta, Egyesült ÁllamokContact: Prateek Gandiga, MD (principal investigator)Toborzás még nem indult
- Johns Hopkins Hospital: Division of RheumatologyBaltimore, Egyesült ÁllamokContact: Zuzana BolognaRésztvevőt keres
- University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & RheumatologyBirmingham, Egyesült ÁllamokContact: Hannah HowellRésztvevőt keres
- University of Chicago, Department of Medicine: RheumatologyChicago, Egyesült ÁllamokContact: J'Heannhehbelle RosierRésztvevőt keres
- Northwell Health: Division of Rheumatology and Allergy-Clinical ImmunologyGreat Neck, Egyesült ÁllamokContact: Galina Marder, MD (principal investigator)Toborzás még nem indult
- University of Texas HoustonHouston, Egyesült ÁllamokContact: Enrique RodriguezRésztvevőt keres
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical ImmunologyPittsburgh, Egyesült ÁllamokContact: Chester Oddis, MD (principal investigator)Toborzás még nem indult
- Mayo Clinic: Division of RheumatologyRochester, Egyesült ÁllamokContact: Jeffery LaivellRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy.
A teljes eredeti leírásKevesebb
The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated 2016 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Myositis Response Criteria, as measured by the Total Improvement Score (TIS)
A vizsgálat 2 csoportja
- Initial Ublituximab Active GroupA vizsgált kezelés
Receives 150 mg Ublituximab at Day 0 and 450 mg Ublituximab at Week 2, followed by 450 mgs of Ublituximab at Weeks 24 and 48. At Week 26, will receive a Placebo dose of 450 mg to maintain the blind.
Kezelés: Ublituximab és Placebo for Ublituximab
- Initial Placebo of ublituximab GroupA vizsgált kezelés
Receives 150 mg Placebo at Day 0 and 450 mg Placebo at Week 2. Receives 150 mg Ublituximab at Week 24 followed by 450 mg Ublituximab at Weeks 26 and 48.
Kezelés: Ublituximab és Placebo for Ublituximab
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Study of Ublituximab in Early, Active, Autoantibody-Positive, IMMune-MedIated NecroTizing Myopathy (AIM01)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 13.